secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001372514-23-000057
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora's KIO-301 shows vision restoration in blind RP patients in Phase 1b
-------------------------------------------------------------------------

- Preliminary Phase 1b ABACUS data: KIO-301 improved light perception in patients with no light perception.
- Patient-reported light/dark contrast perception improved at days 7, 14, and 29 post-injection.
- fMRI showed significantly increased V1 visual cortex activity at days 3 and 15 vs. baseline.
- Quality-of-life score increased 6 points (clinically meaningful threshold is 2–4 points).
- No adverse events reported; dose escalation and full results expected later in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000057/0001372514-23-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000057/kprx-20230427.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer